Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analyst consensus is “Hold” for Contineum Therapeutics, with one sell, one hold and three buy ratings. The average 12-month price target is $20.25, compared with the stock’s reported price of $14.50.
• Shares have traded between $8.12 and $16.91 over the past year, with a market capitalization of approximately $545.5 million. The stock was down 0.2% in the reported session.
• Contineum reported a quarterly loss of $0.40 per share, beating the consensus estimate of a $0.45 loss; analysts expect a full-year loss of $1.68 per share. The company is developing oral therapies targeting neuroscience, inflammation and immunology conditions.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been given a consensus recommendation of "Hold" by the five ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.25.

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Contineum Therapeutics in a report on Friday, July 17th. Morgan Stanley increased their price target on Contineum Therapeutics from $14.00 to $16.00 and gave the company an "equal weight" rating in a research note on Thursday, May 14th. Finally, Royal Bank Of Canada lifted their price objective on Contineum Therapeutics from $22.00 to $23.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st.

Contineum Therapeutics Trading Down 0.2%

Contineum Therapeutics stock opened at $14.50 on Wednesday. Contineum Therapeutics has a 1 year low of $8.12 and a 1 year high of $16.91. The company has a market cap of $545.49 million, a PE ratio of -8.38 and a beta of 0.74. The company's 50-day moving average is $14.20 and its two-hundred day moving average is $13.87.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05. Research analysts forecast that Contineum Therapeutics will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Contineum Therapeutics in the first quarter worth $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Contineum Therapeutics in the 4th quarter valued at $43,000. Qube Research & Technologies Ltd bought a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at $43,000. Marex Group plc bought a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at $45,000. Finally, Royal Bank of Canada increased its position in shares of Contineum Therapeutics by 73.5% in the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company's stock valued at $76,000 after buying an additional 2,454 shares in the last quarter.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source